Sputnik V is the world's first registered COVID-19 vaccine with proven 91.6% efficacy. Sputnik V has been authorized in Kenya.
According to the ministry of health, the Russian vaccine has been authorized by the Pharmacy and poisons board.
According to the Russian company, In an interim analysis of a Phase III clinical trial, Sputnik V showed strong efficacy, immunogenicity and safety results.
The efficacy of Sputnik V against COVID-19 was reported at 91.6%.
The study included data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases.
Efficacy in the elderly group of 2,144 volunteers over 60 years old was 91.8% and did not differ statistically from the 18-60 group.
Vaccine COVID Sputnik V provides full protection against severe cases of COVID-19.
Among the cases analyzed, over 98% of volunteers developed humoral immune response and 100% - cellular immune response.
"It’s true, Sputnik V vaccine has received Emergency Use Authorisation by @ppbkenya It has also received emergency use authorisation from over 65 countries and is already in use in most of these countries, " CAS Mercy Mwangangi said.
The vaccine consists of two jabs. A jab trade at $70 (Sh 7654). Private hospitals have now introduced the new vaccine in their schedule.
Dr Mercy Mwangangi; It’s true, Sputnik V vaccine, has received Emergency Use Authorisation by @ppbkenya
— Ministry of Health (@MOH_Kenya) March 31, 2021
It has also received emergency use authorisation from over 65 countries and is already in use in most of these countries.
Post a Comment
What is your say on this